Clinical Pearls for Clinicians Treating Fibromyalgia

EP: 1.Impact of Brain on Nociplastic Pain for Fibromyalgia

EP: 2.Approaching Management of Fibromyalgia and Unmet Needs in Treatment

EP: 3.Current Treatment Options for Fibromyalgia

EP: 4.Treatment Selection and Strategy for Fibromyalgia Agents

EP: 5.Clinical Pearls for the Management of Fibromyalgia

EP: 6.Overview of Fibromyalgia

EP: 7.Challenges for Patients With Fibromyalgia

EP: 8.FDA-Approved Therapies for Fibromyalgia

EP: 9.Treatment Selection in Fibromyalgia

Now Viewing

EP: 10.Clinical Pearls for Clinicians Treating Fibromyalgia

EP: 11.Future Developments in Fibromyalgia Treatment

This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.

Fibromyalgia may raise concerns for physicians regarding time consumption and emotional burden. Addressing these concerns requires upfront communication, explaining the neurobiology behind fibromyalgia to reduce stigma, particularly associated with psychological perceptions. With improved treatment approaches, managing fibromyalgia becomes more rewarding, especially when patients respond well to their treatment regimen. When patients have comorbid conditions, such as autoimmune diseases like rheumatoid arthritis or lupus, it's crucial to control both conditions concurrently. Employing current medications, biologics, and targeted synthetic disease-modifying drugs to manage inflammation and symptoms is essential. Simultaneously, acknowledging the presence of central sensitization or fibromyalgia is vital, fostering acceptance through patient-friendly language. Using terms like "central sensitization" can mitigate the stigma around fibromyalgia. Collaboratively pursuing nonpharmacological approaches alongside prescribed treatments enhances patient acceptance and makes the overall treatment approach more rewarding for both the physician and the patient.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.